Seminars in Nephrology
Volume 29, Issue 4 , Pages 370-378 , July 2009

Emerging Topics in Pediatric Bone and Mineral Disorders 2008

  • Charles P. McKay, MD

      Affiliations

    • Department of Pediatrics, Levine Children's Hospital at Carolinas Medical Center, Charlotte, NC
    • Corresponding Author InformationAddress reprint requests to Charles P. McKay, MD, Director of Pediatric Dialysis, Associate Residency Program Director, Department of Pediatrics, Levine Children's Hospital at Carolinas Medical Center, PO Box 32861, Charlotte, NC 28232-2861
    • ,
  • Anthony Portale, MD

      Affiliations

    • Department of Pediatrics, University of California San Francisco, San Francisco, CA

References 

  1. Chattopadhyay N, Mithal A, Brown E. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev. 1996;17:289–307
  2. Brown EM, MacLeod RJ. Extracellular calcium sensing and intracellular calcium signaling. Physiol Rev. 2001;81:240–297
  3. Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int. 1996;50:2129–2139
  4. Foley TP, Harrison HC, Arnaud CD, Harrison HE. Familial benign hypercalcemia. J Pediatr. 1972;81:1060–1067
  5. Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW, Lasker RD. The hypocalciuric or benign variant of familial hypercalcemia: clinical, and biochemical features in fifteen kindreds. Medicine. 1981;60:397–412
  6. Menko FH, Bijvoet OLM, Fronen JLHH, Sandler LM, Adami S, O'Riordan JLH, et al. Familial benign hypercalcaemia. Q J Med. 1983;52:120–140
  7. Attie MF, Gill JR, Stock JL, Spiegel AM, Downs RW, Levine MA, et al. Urinary calcium excretion in familial hypocalciuric hypercalcemia. J Clin Invest. 1983;72:667–676
  8. Spiegel AM, Harrison HE, Marx SJ, Brown EM, Aurbach GD. Neonatal primary hyperparathyroidism with autosomal dominant inheritance. J Pediatr. 1977;90:269–272
  9. Marx SJ, Attie MF, Speigel AM, Levine MA, Lasker RD, Fox M. An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N Engl J Med. 1982;306:257–264
  10. Matsuo M, Okita K, Takemine H, Fujita T. Neonatal primary hyperparathyroidism in familial hypocalciuric hypercalcemia. Am J Dis Child. 1982;136:728–731
  11. Cooper L, Wertheimer J, Levey R, Brown E, Leboff M, Wilkinson R, et al. Severe primary hyperparathyroidism in a neonate with two hypercalcemic parents: management with parathyroidectomy and heterotopic autotransplantation. Pediatrics. 1986;78:263–268
  12. Marx SJ, Fraser D, Rapoport A. Familial hypocalciuric hypercalcemia (Mild expression of the gene in heterozygotes and severe expression in homozygotes). Am J Med. 1985;78:15–22
  13. Pollak MR, Brown EM, Chou Y-HW, Hebert SC, Marx SJ, Steinman B, et al. Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;75:1297–1303
  14. Pearce SHS, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, et al. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest. 1995;96:2683–2692
  15. Pollak MR, Chou Y-HW, Marx SJ, Steinman B, Cole DEC, Brandi ML, et al. Familial hypocalciuiric hypercalcemia and neonatal severe hyperparathyroidism (Effects of mutant gene dosage on phenotype). J Clin Invest. 1994;93:1108–1112
  16. Matsuo M, Okita K, Takemine H, Fujita T. Neonatal primary hyperparathyroidism in familial hypocalciuric hypercalcemia. Am J Dis Child. 1982;136:728–731
  17. Brown EM. Mutant extracellular calcium-sensing receptors and severity of disease [editorial]. J Clin Endocrinol Metab. 2005;90:1246–1248
  18. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, et al. Autosomal dominant hypocalcemia cause by a Ca2+-sensing receptor gene mutation. Nat Genet. 1994;8:303–307
  19. Pearce SHS, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med. 1996;335:1115–1122
  20. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasgawa Y, Okazaki R, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet. 2002;360:692–694
  21. Hebert SC, Riccardi D, Geibel JP. The calcium-sensing receptor. In:  Alpern RJ,  Hebert SC editor. 3rd ed.. Seldin and Giebisch's the kidney. Vol 2:Philadelphia: Elsevier Saunders; 2008;p. 1785–1802
  22. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288:F253–F264
  23. Goodman WG, Veldhuis JD, Belin TR, Van Herle AJ, Juppner H, Salusky IB. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinal Metab. 1998;83:2765–2772
  24. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800
  25. Evennpoel P. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int. 2008;74:265–275
  26. Alon U, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjunctive treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3:658–664
  27. Silverstein D, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol. 2008;23:1817–1822
  28. Muscheites J, Wigger M, Druekler E, Fischer D-C, Kundt G, Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol. 2008;23:1823–1829
  29. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev. 2000;80:1373–1409
  30. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–348
  31. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774
  32. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500–6505
  33. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet. 1995;11:130–136
  34. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656–1663
  35. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146:5358–5364
  36. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997;82:674–681
  37. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22:520–526
  38. Kruse K, Woelfel D, Strom TM, Storm TM. Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res. 2001;55:305–308
  39. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079–2086
  40. Scriver CR, Reade T, Halal F, Costa T, Cole DE. Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3. Arch Dis Child. 1981;56:203–207
  41. Lorenz-Depiereux B, Bastepe M, et-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248–1250
  42. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–1315
  43. Ye L, Mishina Y, Chen D, Huang H, Dallas SL, Dallas MR, et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem. 2005;280:6197–6203
  44. Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med. 1985;312:611–617
  45. Lorenz-Depiereux B, et-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet. 2006;78:193–201
  46. Econs MJ, Drezner MK. Tumor-induced osteomalacia—unveiling a new hormone. N Engl J Med. 1994;330:1679–1681
  47. Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–162
  48. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36:579–581
  49. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004;35:455–462
  50. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology. 2005;146:3883–3891
  51. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact. 2007;7:318–319
  52. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007;194:1–10
  53. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279
  54. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65:1943–1946
  55. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592
  56. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–2608

PII: S0270-9295(09)00057-6

doi: 10.1016/j.semnephrol.2009.03.020

Seminars in Nephrology
Volume 29, Issue 4 , Pages 370-378 , July 2009

Article Tools